StockData

Amylyx Pharmaceuticals vs vTv Therapeutics

AMLX and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMLX and VTVT compare

Amylyx Pharmaceuticals is the larger company, worth 45 times as much as vTv Therapeutics ($3.1B against $68.4M).

vTv Therapeutics scores higher on the StockData Score (11 against 6 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMLXVTVT
Size and price
Market cap$3.1B$68.4M
Share price$27.52$17.29
Change, 1 year117%−43.9%
Change, 5 years168%−67.7%
Beta (5Y)0.540.08
Employees13626
StockData Score
Total score611 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score02 (better)
Health score6 (better)5
Dividend score00
Valuation
P/S–1.9×
P/B12.8×0.9× (better)
Fair value–$44.97
Margin of safety–61.6%
Growth
Revenue growth (TTM)–216600%
Profitability
Operating margin–−25.1%
Net margin–−12.9%
Return on equity−74.7%−11.7% (better)
Financial health
Debt / equity0.000.00
Current ratio12.1212.48 (better)
Altman Z-score67.06 (better)0.71
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%40.6%
Held by insiders7.8%26.3%
Insider net buying, 12 months−$17.2M–
Short interest, % of float12.5%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.